AR043929A1 - Fases cristalinas de un inhibidor del hcv - Google Patents

Fases cristalinas de un inhibidor del hcv

Info

Publication number
AR043929A1
AR043929A1 ARP040101010A ARP040101010A AR043929A1 AR 043929 A1 AR043929 A1 AR 043929A1 AR P040101010 A ARP040101010 A AR P040101010A AR P040101010 A ARP040101010 A AR P040101010A AR 043929 A1 AR043929 A1 AR 043929A1
Authority
AR
Argentina
Prior art keywords
crystal phases
hcv inhibitor
hcv
inhibitor
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP040101010A
Other languages
English (en)
Inventor
Michael Kenneth Cerreta
John Andrew Smoliga
Richard J Varsolona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR043929A1 publication Critical patent/AR043929A1/es
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Se refiere a nuevas fases cristalinas del compuesto de fórmula (1), a métodos para su preparación, a sus composiciones farmacéuticas, y a su uso en el tratamiento de la infección de hepatitis C viral (HCV).
ARP040101010A 2003-03-27 2004-03-26 Fases cristalinas de un inhibidor del hcv Suspension/Interruption AR043929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45818803P 2003-03-27 2003-03-27

Publications (1)

Publication Number Publication Date
AR043929A1 true AR043929A1 (es) 2005-08-17

Family

ID=33131764

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101010A Suspension/Interruption AR043929A1 (es) 2003-03-27 2004-03-26 Fases cristalinas de un inhibidor del hcv

Country Status (7)

Country Link
US (1) US20040229777A1 (es)
AR (1) AR043929A1 (es)
CL (1) CL2004000648A1 (es)
PE (1) PE20041069A1 (es)
TW (1) TW200505944A (es)
UY (1) UY28240A1 (es)
WO (1) WO2004087741A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
DK1999129T3 (da) 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
US8048862B2 (en) 2008-04-15 2011-11-01 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2687526A1 (en) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
SI2451438T1 (sl) 2009-07-07 2014-04-30 Boehringer Ingelheim International Gmbh Farmacevtski sestavek za inhibitor virusne proteaze hepatitisa C
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
EP2513113B1 (en) 2009-12-18 2018-08-01 Idenix Pharmaceuticals LLC 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8530497B2 (en) * 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2861041A1 (en) * 2012-01-12 2013-07-18 Boehringer Ingelheim International Gmbh Stabilized pharmaceutical formulations of a potent hcv inhibitor
JP2015533124A (ja) 2012-10-08 2015-11-19 アッヴィ・インコーポレイテッド Ｈｃｖプロテアーゼ阻害剤を作製するのに有用な化合物
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CA2948902C (en) * 2014-06-06 2022-11-22 Abbvie Inc. Crystal forms of hcv protease inhibitors and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20040138109A1 (en) * 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease

Also Published As

Publication number Publication date
WO2004087741A1 (en) 2004-10-14
US20040229777A1 (en) 2004-11-18
CL2004000648A1 (es) 2005-02-04
UY28240A1 (es) 2004-11-08
TW200505944A (en) 2005-02-16
PE20041069A1 (es) 2005-02-25

Similar Documents

Publication Publication Date Title
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
HRP20060254A2 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
GEP20094751B (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
IS7533A (is) Lifrarbólgu C-veirutálmar
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
NO20075616L (no) Tripeptider som hepatitt C virus inhibitorer
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
NO20044808L (no) Heterosykliske sulfonamider som er hepatitt C virus inhibitorer
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20080123A1 (es) Composiciones farmaceuticas que contienen vx-950 en el tratamiento de hepatitis c
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
CO6450600A2 (es) Inhibidores de anillo fusionado de hepatitis c
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.

Legal Events

Date Code Title Description
FB Suspension of granting procedure